サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1412524

止血診断薬市場：製品、検査タイプ、最終用途別-2024-2030年の世界予測

Hemostasis Diagnostics Market by Product (Consumables, Laboratory Analyzers, Point-of-Care Testing Systems), Test Type (Activated Clotting Time, Activated Partial Thromboplastin Time, D Dimer Test), End Use - Global Forecast 2024-2030
出版日: | 発行: 360iResearch | ページ情報: 英文 180 Pages | 納期: 即日から翌営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=155.11円
止血診断薬市場：製品、検査タイプ、最終用途別-2024-2030年の世界予測
出版日: 2024年01月15日
発行: 360iResearch
ページ情報: 英文 180 Pages
納期: 即日から翌営業日
ご注意事項 :
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 図表
  • 目次
概要

止血診断薬市場規模は2023年に5億7,932万米ドルと推定され、2024年には6億2,010万米ドルに達すると予測され、CAGR 8.04%で2030年には9億9,577万米ドルに達する見込みです。

止血診断薬の世界市場

主な市場の統計
基準年[2023］ 5億7,932万米ドル
予測年[2024］ 6億2,010万米ドル
予測年［2030] 9億9,577万米ドル
CAGR（%） 8.04%
止血診断薬 Market-IMG1

FPNVポジショニング・マトリックス

FPNVポジショニングマトリックスは止血診断薬市場を評価する上で極めて重要です。事業戦略と製品満足度に関連する主要指標を調査し、ベンダーの包括的な評価を提供します。この綿密な分析により、ユーザーは各自の要件に沿った十分な情報に基づいた意思決定を行うことができます。評価に基づき、ベンダーは成功の度合いが異なる4つの象限に分類されます：フォアフロント（F）、パスファインダー（P）、ニッチ（N）、バイタル（V）です。

市場シェア分析

市場シェア分析は、止血診断薬市場におけるベンダーの現状について、洞察に満ちた詳細な調査を提供する包括的なツールです。全体的な収益、顧客ベース、その他の主要指標についてベンダーの貢献度を綿密に比較・分析することで、各社の業績や市場シェア争いの際に直面する課題について理解を深めることができます。さらに、この分析により、調査対象基準年に観察された蓄積、断片化の優位性、合併の特徴などの要因を含む、この分野の競争特性に関する貴重な洞察が得られます。このように詳細レベルを拡大することで、ベンダーはより多くの情報に基づいた意思決定を行い、市場での競争力を獲得するための効果的な戦略を考案することができます。

本レポートは、以下の側面に関する貴重な洞察を提供しています：

1-市場の浸透度：主要企業が提供する市場に関する包括的な情報を提示しています。

2-市場の開拓：有利な新興市場を深く掘り下げ、成熟した市場セグメントにおける浸透度を分析しています。

3-市場の多様化：新製品の発売、未開拓の地域、最近の開発、投資に関する詳細な情報を提供します。

4-競合の評価と情報：主要企業の市場シェア、戦略、製品、認証、規制当局の承認、特許状況、製造能力について徹底的な評価を行います。

5-製品開発およびイノベーション：将来の技術、研究開発活動、画期的な製品開発に関する知的洞察を提供します。

本レポートは、以下のような主要な質問に対応しています：

1-止血診断薬市場の市場規模および予測は？

2-止血診断薬市場の予測期間中に投資を検討すべき製品、セグメント、用途、分野は何か？

3-止血診断薬市場における技術動向と規制の枠組みは？

4-止血診断薬市場における主要ベンダーの市場シェアは？

5-止血診断薬市場への参入に適した形態や戦略的手段は？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

  • 市場力学
    • 促進要因
      • 止血障害の発生率が世界的に増加
      • ポイントオブケア検査ソリューションへの傾向
      • 止血障害に対する認識の高まりと早期診断の重視
    • 抑制要因
      • 高額な診断コストと製品リコールの発生率
    • 機会
      • 個別化医療アプローチを活用してオーダーメイドの治療を提供
      • 止血診断法の進歩
    • 課題
      • 止血診断のための複雑な検査方法
  • 市場セグメンテーション分析
  • 市場動向分析
  • 高インフレの累積的影響
  • ポーターのファイブフォース分析
  • バリューチェーンとクリティカルパス分析
  • 規制の枠組み

第6章 止血診断薬市場：製品別

  • 消耗品
  • 臨床検査用分析装置
  • ポイントオブケア検査システム

第7章 止血診断薬市場テストタイプ別

  • 活性化凝固時間
  • 活性化部分トロンボプラスチン時間
  • Dダイマーテスト
  • フィブリノゲン検査
  • 血小板凝集検査
  • プロトロンビン時間（PT）検査

第8章 止血診断薬市場：最終用途別

  • 在宅ケア環境
  • 病院・診療所
  • 独立した診断研究所

第9章 南北アメリカの止血診断薬市場

  • アルゼンチン
  • ブラジル
  • カナダ
  • メキシコ
  • 米国

第10章 アジア太平洋地域の止血診断薬市場

  • オーストラリア
  • 中国
  • インド
  • インドネシア
  • 日本
  • マレーシア
  • フィリピン
  • シンガポール
  • 韓国
  • 台湾
  • タイ
  • ベトナム

第11章 欧州・中東・アフリカの止血診断薬市場

  • デンマーク
  • エジプト
  • フィンランド
  • フランス
  • ドイツ
  • イスラエル
  • イタリア
  • オランダ
  • ナイジェリア
  • ノルウェー
  • ポーランド
  • カタール
  • ロシア
  • サウジアラビア
  • 南アフリカ
  • スペイン
  • スウェーデン
  • スイス
  • トルコ
  • アラブ首長国連邦
  • 英国

第12章 競合情勢

  • FPNVポジショニングマトリクス
  • 市場シェア分析：主要企業別
  • 競合シナリオ主要企業別の分析

第13章 競争力のあるポートフォリオ

  • 主要な企業プロファイル
    • Abbott Laboratories
    • ARUP Laboratories
    • Becton, Dickinson and Company
    • Bio-Rad Laboratories, Inc.
    • bioMerieux SA
    • Danaher Corporation
    • DiaPharma Group, Inc.
    • F. Hoffmann-La Roche Ltd.
    • Grifols, S.A.
    • Haemonetics Corporation
    • Helena Laboratories Corporation
    • HemoSonics, LLC
    • HORIBA Group
    • Laboratory Corporation of America Holdings
    • Medtronic PLC
    • Merck & Co., Inc.
    • Randox Laboratories Ltd.
    • Siemens AG
    • Stago Group
    • Sysmex America, Inc.
    • Sysmex Europe SE
    • Technoclone Herstellung von Diagnostika und Arzneimitteln GmbH
    • Thermo Fisher Scientific Inc.
    • Werfen, S.A.
  • 主要な製品ポートフォリオ

第14章 付録

  • ディスカッションガイド
  • ライセンスと価格について
図表

LIST OF FIGURES

  • FIGURE 1. HEMOSTASIS DIAGNOSTICS MARKET RESEARCH PROCESS
  • FIGURE 2. HEMOSTASIS DIAGNOSTICS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. HEMOSTASIS DIAGNOSTICS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY REGION, 2023 VS 2030 (%)
  • FIGURE 5. HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. HEMOSTASIS DIAGNOSTICS MARKET DYNAMICS
  • FIGURE 7. HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2023 VS 2030 (%)
  • FIGURE 8. HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 9. HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2023 VS 2030 (%)
  • FIGURE 10. HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 11. HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY END USE, 2023 VS 2030 (%)
  • FIGURE 12. HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY END USE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 13. AMERICAS HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 14. AMERICAS HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 15. UNITED STATES HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 16. UNITED STATES HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 17. ASIA-PACIFIC HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 18. ASIA-PACIFIC HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 21. HEMOSTASIS DIAGNOSTICS MARKET, FPNV POSITIONING MATRIX, 2023
  • FIGURE 22. HEMOSTASIS DIAGNOSTICS MARKET SHARE, BY KEY PLAYER, 2023

LIST OF TABLES

  • TABLE 1. HEMOSTASIS DIAGNOSTICS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. HEMOSTASIS DIAGNOSTICS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 6. HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY CONSUMABLES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 7. HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY LABORATORY ANALYZERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 8. HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY POINT-OF-CARE TESTING SYSTEMS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 10. HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY ACTIVATED CLOTTING TIME, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY ACTIVATED PARTIAL THROMBOPLASTIN TIME, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY D DIMER TEST, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY FIBRINOGEN TEST, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY PLATELET AGGREGATION TEST, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY PROTHROMBIN TIME (PT) TEST, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 17. HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY HOME CARE SETTING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY HOSPITALS/CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY INDEPENDENT DIAGNOSTIC LABORATORIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. AMERICAS HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 21. AMERICAS HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 22. AMERICAS HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 23. AMERICAS HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 24. ARGENTINA HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 25. ARGENTINA HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 26. ARGENTINA HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 27. BRAZIL HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 28. BRAZIL HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 29. BRAZIL HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 30. CANADA HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 31. CANADA HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 32. CANADA HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 33. MEXICO HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 34. MEXICO HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 35. MEXICO HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 36. UNITED STATES HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 37. UNITED STATES HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 38. UNITED STATES HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 39. UNITED STATES HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 40. ASIA-PACIFIC HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 41. ASIA-PACIFIC HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 42. ASIA-PACIFIC HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 43. ASIA-PACIFIC HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 44. AUSTRALIA HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 45. AUSTRALIA HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 46. AUSTRALIA HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 47. CHINA HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 48. CHINA HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 49. CHINA HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 50. INDIA HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 51. INDIA HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 52. INDIA HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 53. INDONESIA HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 54. INDONESIA HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 55. INDONESIA HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 56. JAPAN HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 57. JAPAN HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 58. JAPAN HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 59. MALAYSIA HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 60. MALAYSIA HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 61. MALAYSIA HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 62. PHILIPPINES HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 63. PHILIPPINES HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 64. PHILIPPINES HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 65. SINGAPORE HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 66. SINGAPORE HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 67. SINGAPORE HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 68. SOUTH KOREA HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 69. SOUTH KOREA HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 70. SOUTH KOREA HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 71. TAIWAN HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 72. TAIWAN HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 73. TAIWAN HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 74. THAILAND HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 75. THAILAND HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 76. THAILAND HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 77. VIETNAM HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 78. VIETNAM HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 79. VIETNAM HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 80. EUROPE, MIDDLE EAST & AFRICA HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 81. EUROPE, MIDDLE EAST & AFRICA HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 82. EUROPE, MIDDLE EAST & AFRICA HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 83. EUROPE, MIDDLE EAST & AFRICA HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 84. DENMARK HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 85. DENMARK HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 86. DENMARK HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 87. EGYPT HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 88. EGYPT HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 89. EGYPT HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 90. FINLAND HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 91. FINLAND HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 92. FINLAND HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 93. FRANCE HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 94. FRANCE HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 95. FRANCE HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 96. GERMANY HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 97. GERMANY HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 98. GERMANY HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 99. ISRAEL HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 100. ISRAEL HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 101. ISRAEL HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 102. ITALY HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 103. ITALY HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 104. ITALY HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 105. NETHERLANDS HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 106. NETHERLANDS HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 107. NETHERLANDS HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 108. NIGERIA HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 109. NIGERIA HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 110. NIGERIA HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 111. NORWAY HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 112. NORWAY HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 113. NORWAY HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 114. POLAND HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 115. POLAND HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 116. POLAND HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 117. QATAR HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 118. QATAR HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 119. QATAR HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 120. RUSSIA HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 121. RUSSIA HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 122. RUSSIA HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 123. SAUDI ARABIA HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 124. SAUDI ARABIA HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 125. SAUDI ARABIA HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 126. SOUTH AFRICA HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 127. SOUTH AFRICA HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 128. SOUTH AFRICA HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 129. SPAIN HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 130. SPAIN HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 131. SPAIN HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 132. SWEDEN HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 133. SWEDEN HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 134. SWEDEN HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 135. SWITZERLAND HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 136. SWITZERLAND HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 137. SWITZERLAND HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 138. TURKEY HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 139. TURKEY HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 140. TURKEY HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 141. UNITED ARAB EMIRATES HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 142. UNITED ARAB EMIRATES HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 143. UNITED ARAB EMIRATES HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 144. UNITED KINGDOM HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 145. UNITED KINGDOM HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 146. UNITED KINGDOM HEMOSTASIS DIAGNOSTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 147. HEMOSTASIS DIAGNOSTICS MARKET, FPNV POSITIONING MATRIX, 2023
  • TABLE 148. HEMOSTASIS DIAGNOSTICS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 149. HEMOSTASIS DIAGNOSTICS MARKET LICENSE & PRICING
目次
Product Code: MRR-DD0700E81E5A

[180 Pages Report] The Hemostasis Diagnostics Market size was estimated at USD 579.32 million in 2023 and expected to reach USD 620.10 million in 2024, at a CAGR 8.04% to reach USD 995.77 million by 2030.

Global Hemostasis Diagnostics Market

KEY MARKET STATISTICS
Base Year [2023] USD 579.32 million
Estimated Year [2024] USD 620.10 million
Forecast Year [2030] USD 995.77 million
CAGR (%) 8.04%
Hemostasis Diagnostics Market - IMG1

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Hemostasis Diagnostics Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Hemostasis Diagnostics Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Hemostasis Diagnostics Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, ARUP Laboratories, Becton, Dickinson and Company, Bio-Rad Laboratories, Inc., bioMerieux SA, Danaher Corporation, DiaPharma Group, Inc., F. Hoffmann-La Roche Ltd., Grifols, S.A., Haemonetics Corporation, Helena Laboratories Corporation, HemoSonics, LLC, HORIBA Group, Laboratory Corporation of America Holdings, Medtronic PLC, Merck & Co., Inc., Randox Laboratories Ltd., Siemens AG, Stago Group, Sysmex America, Inc., Sysmex Europe SE, Technoclone Herstellung von Diagnostika und Arzneimitteln GmbH, Thermo Fisher Scientific Inc., and Werfen, S.A..

Market Segmentation & Coverage

This research report categorizes the Hemostasis Diagnostics Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Product
    • Consumables
    • Laboratory Analyzers
    • Point-of-Care Testing Systems
  • Test Type
    • Activated Clotting Time
    • Activated Partial Thromboplastin Time
    • D Dimer Test
    • Fibrinogen Test
    • Platelet Aggregation Test
    • Prothrombin Time (PT) Test
  • End Use
    • Home Care Setting
    • Hospitals/Clinics
    • Independent Diagnostic Laboratories
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.

2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.

3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.

4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.

5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Hemostasis Diagnostics Market?

2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Hemostasis Diagnostics Market?

3. What are the technology trends and regulatory frameworks in the Hemostasis Diagnostics Market?

4. What is the market share of the leading vendors in the Hemostasis Diagnostics Market?

5. Which modes and strategic moves are suitable for entering the Hemostasis Diagnostics Market?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Limitations
  • 1.7. Assumptions
  • 1.8. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

  • 4.1. Introduction
  • 4.2. Hemostasis Diagnostics Market, by Region

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increase in incidences of hemostasis disorders worlwide
      • 5.1.1.2. Inclination toward point-of-care testing solutions
      • 5.1.1.3. Growing awareness of hemostasis disorders and emphasis on early diagnosis
    • 5.1.2. Restraints
      • 5.1.2.1. High cost of diagnosis and incidences of product recall
    • 5.1.3. Opportunities
      • 5.1.3.1. Utilization of personalized medicine approach to deliver tailored treatments
      • 5.1.3.2. Advancements in diagnostic methods for hemostasis
    • 5.1.4. Challenges
      • 5.1.4.1. Complex testing methods for hemostasis diagnosis
  • 5.2. Market Segmentation Analysis
  • 5.3. Market Trend Analysis
  • 5.4. Cumulative Impact of High Inflation
  • 5.5. Porter's Five Forces Analysis
    • 5.5.1. Threat of New Entrants
    • 5.5.2. Threat of Substitutes
    • 5.5.3. Bargaining Power of Customers
    • 5.5.4. Bargaining Power of Suppliers
    • 5.5.5. Industry Rivalry
  • 5.6. Value Chain & Critical Path Analysis
  • 5.7. Regulatory Framework

6. Hemostasis Diagnostics Market, by Product

  • 6.1. Introduction
  • 6.2. Consumables
  • 6.3. Laboratory Analyzers
  • 6.4. Point-of-Care Testing Systems

7. Hemostasis Diagnostics Market, by Test Type

  • 7.1. Introduction
  • 7.2. Activated Clotting Time
  • 7.3. Activated Partial Thromboplastin Time
  • 7.4. D Dimer Test
  • 7.5. Fibrinogen Test
  • 7.6. Platelet Aggregation Test
  • 7.7. Prothrombin Time (PT) Test

8. Hemostasis Diagnostics Market, by End Use

  • 8.1. Introduction
  • 8.2. Home Care Setting
  • 8.3. Hospitals/Clinics
  • 8.4. Independent Diagnostic Laboratories

9. Americas Hemostasis Diagnostics Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Hemostasis Diagnostics Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Hemostasis Diagnostics Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. FPNV Positioning Matrix
  • 12.2. Market Share Analysis, By Key Player
  • 12.3. Competitive Scenario Analysis, By Key Player

13. Competitive Portfolio

  • 13.1. Key Company Profiles
    • 13.1.1. Abbott Laboratories
    • 13.1.2. ARUP Laboratories
    • 13.1.3. Becton, Dickinson and Company
    • 13.1.4. Bio-Rad Laboratories, Inc.
    • 13.1.5. bioMerieux SA
    • 13.1.6. Danaher Corporation
    • 13.1.7. DiaPharma Group, Inc.
    • 13.1.8. F. Hoffmann-La Roche Ltd.
    • 13.1.9. Grifols, S.A.
    • 13.1.10. Haemonetics Corporation
    • 13.1.11. Helena Laboratories Corporation
    • 13.1.12. HemoSonics, LLC
    • 13.1.13. HORIBA Group
    • 13.1.14. Laboratory Corporation of America Holdings
    • 13.1.15. Medtronic PLC
    • 13.1.16. Merck & Co., Inc.
    • 13.1.17. Randox Laboratories Ltd.
    • 13.1.18. Siemens AG
    • 13.1.19. Stago Group
    • 13.1.20. Sysmex America, Inc.
    • 13.1.21. Sysmex Europe SE
    • 13.1.22. Technoclone Herstellung von Diagnostika und Arzneimitteln GmbH
    • 13.1.23. Thermo Fisher Scientific Inc.
    • 13.1.24. Werfen, S.A.
  • 13.2. Key Product Portfolio

14. Appendix

  • 14.1. Discussion Guide
  • 14.2. License & Pricing